Related Experiment Videos
Management of pneumococcal meningitis
1Texas Children's Hospital, Houston, USA.
Abstract:
During the past decade antibiotic resistance among Streptococcus pneumoniae isolates has complicated the empiric approach to and treatment of pneumococcal meningitis. Standard empiric therapy for suspected bacterial meningitis for infants and children older than 1 month of age is the combination of cefotaxime or ceftriaxone and vancomycin. Treatment is modified after antimicrobial susceptibilities are available. The optimal treatment of pneumococcal meningitis caused by strains with a cefotaxime/ceftriaxone MIC >2 microg/ml is unknown, although the addition of rifampin to the initial combination is generally recommended. The role of newer agents including quinolones is under investigation. Dexamethasone remains the only adjunctive antiinflammatory therapy to consider. The empiric approach to the child with suspected bacterial meningitis who has received the pneumococcal conjugate vaccine currently remains unchanged.
Insights
Antibiotic resistance in Streptococcus pneumoniae complicates meningitis treatment. Current empiric therapy involves cefotaxime/ceftriaxone and vancomycin, with rifampin recommended for resistant strains.
Area of Science:
- Infectious Diseases
- Microbiology
- Pediatrics
Background:
- Antibiotic resistance in Streptococcus pneumoniae has increased, complicating pneumococcal meningitis treatment.
- Standard empiric therapy for bacterial meningitis in children over 1 month includes cefotaxime/ceftriaxone plus vancomycin.
- Treatment requires adjustment based on antimicrobial susceptibility testing.
Purpose of the Study:
- To review current treatment strategies for pneumococcal meningitis in light of rising antibiotic resistance.
- To discuss optimal therapeutic approaches for meningitis caused by resistant Streptococcus pneumoniae strains.
- To evaluate the role of adjunctive therapies and newer antimicrobial agents.
Main Methods:
- Review of current clinical guidelines and literature on pneumococcal meningitis treatment.
- Analysis of antimicrobial resistance patterns of Streptococcus pneumoniae.
- Evaluation of therapeutic options for meningitis with high-level cephalosporin resistance.
Main Results:
- Cefotaxime/ceftriaxone resistance in Streptococcus pneumoniae poses a challenge to standard empiric meningitis therapy.
- For strains with cefotaxime/ceftriaxone MIC >2 microg/ml, optimal treatment is not established, but adding rifampin is generally advised.
- Dexamethasone is the sole recommended anti-inflammatory agent.
- The empiric approach for vaccinated children remains unchanged.
Conclusions:
- Managing pneumococcal meningitis requires careful consideration of evolving antibiotic resistance patterns.
- Rifampin addition is a key strategy for treating meningitis caused by cephalosporin-resistant Streptococcus pneumoniae.
- Further research is needed on newer agents like quinolones for resistant infections.